The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform

Jian Huang - One of the best experts on this subject based on the ideXlab platform.

  • bcor mutation and tls erg expression in acute myeloid leukemia with Monoclonal Immunoglobulinemia
    2019
    Co-Authors: Jingxia Jin, Shuna Luo, Jian Huang
    Abstract:

    Acute myeloid leukemia (AML) originates from the abnormal clonal proliferation of myeloblasts. Immunoglobulin is secreted by B cells. AML with Monoclonal antibody often indicates a poor prognosis. Here we report a case of BCOR mutation and TLS-ERG expression in AML with Monoclonal Immunoglobulinemia. After chemotherapy, the patient achieved bone marrow complete remission. BCOR mutation and TLS-ERG fusion gene in patient's bone marrow were not detected, at the same time, peripheral blood Monoclonal immunoglobulin also disappeared. BCOR mutation or TLS-ERG fusion gene expression is associated with poor prognosis, AML with Monoclonal immunoglobulin may have the same prognostic significance.

Jingxia Jin - One of the best experts on this subject based on the ideXlab platform.

  • bcor mutation and tls erg expression in acute myeloid leukemia with Monoclonal Immunoglobulinemia
    2019
    Co-Authors: Jingxia Jin, Shuna Luo, Jian Huang
    Abstract:

    Acute myeloid leukemia (AML) originates from the abnormal clonal proliferation of myeloblasts. Immunoglobulin is secreted by B cells. AML with Monoclonal antibody often indicates a poor prognosis. Here we report a case of BCOR mutation and TLS-ERG expression in AML with Monoclonal Immunoglobulinemia. After chemotherapy, the patient achieved bone marrow complete remission. BCOR mutation and TLS-ERG fusion gene in patient's bone marrow were not detected, at the same time, peripheral blood Monoclonal immunoglobulin also disappeared. BCOR mutation or TLS-ERG fusion gene expression is associated with poor prognosis, AML with Monoclonal immunoglobulin may have the same prognostic significance.

Shuna Luo - One of the best experts on this subject based on the ideXlab platform.

  • bcor mutation and tls erg expression in acute myeloid leukemia with Monoclonal Immunoglobulinemia
    2019
    Co-Authors: Jingxia Jin, Shuna Luo, Jian Huang
    Abstract:

    Acute myeloid leukemia (AML) originates from the abnormal clonal proliferation of myeloblasts. Immunoglobulin is secreted by B cells. AML with Monoclonal antibody often indicates a poor prognosis. Here we report a case of BCOR mutation and TLS-ERG expression in AML with Monoclonal Immunoglobulinemia. After chemotherapy, the patient achieved bone marrow complete remission. BCOR mutation and TLS-ERG fusion gene in patient's bone marrow were not detected, at the same time, peripheral blood Monoclonal immunoglobulin also disappeared. BCOR mutation or TLS-ERG fusion gene expression is associated with poor prognosis, AML with Monoclonal immunoglobulin may have the same prognostic significance.

Li-hui Peng - One of the best experts on this subject based on the ideXlab platform.

  • Waldenström macroglobulinemia: Progress in evidence-based medicine and updates of consensus panel recommendation
    2013
    Co-Authors: Jian Hou, Li-hui Peng
    Abstract:

    Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder primarily characterized by infiltration of lymphoplasmacytic cells into the bone marrow, along with demonstration of Monoclonal Immunoglobulinemia M(IgM). Recent studies have demonstrated the MYD88 L265P somatic mutation contributes to the pathogenesis of WM. Mutated MYD88 activates NF-κB through a series of signals, which results in abnormal propagation of B cells. Clinical manifestation mainly consisted of tissue injuries attributable to tissue infiltration and Monoclonal IgM. WM should be differentiated from lymphomas producing Monoclonal IgM, and detection of MYD88 L265P mutation provides a new way to differentiate WM from other similar diseases. At present recommended treatments for WM include alkylating agents, nucleoside analogues, bortezomib, rituximab etc

Jian Hou - One of the best experts on this subject based on the ideXlab platform.

  • Waldenström macroglobulinemia: Progress in evidence-based medicine and updates of consensus panel recommendation
    2013
    Co-Authors: Jian Hou, Li-hui Peng
    Abstract:

    Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder primarily characterized by infiltration of lymphoplasmacytic cells into the bone marrow, along with demonstration of Monoclonal Immunoglobulinemia M(IgM). Recent studies have demonstrated the MYD88 L265P somatic mutation contributes to the pathogenesis of WM. Mutated MYD88 activates NF-κB through a series of signals, which results in abnormal propagation of B cells. Clinical manifestation mainly consisted of tissue injuries attributable to tissue infiltration and Monoclonal IgM. WM should be differentiated from lymphomas producing Monoclonal IgM, and detection of MYD88 L265P mutation provides a new way to differentiate WM from other similar diseases. At present recommended treatments for WM include alkylating agents, nucleoside analogues, bortezomib, rituximab etc